PE20001047A1 - METODO PARA TRATAR ATEROESCLEROSIS EMPLEANDO UN INHIBIDOR DE aP2 Y COMBINACION - Google Patents

METODO PARA TRATAR ATEROESCLEROSIS EMPLEANDO UN INHIBIDOR DE aP2 Y COMBINACION

Info

Publication number
PE20001047A1
PE20001047A1 PE1999000944A PE00094499A PE20001047A1 PE 20001047 A1 PE20001047 A1 PE 20001047A1 PE 1999000944 A PE1999000944 A PE 1999000944A PE 00094499 A PE00094499 A PE 00094499A PE 20001047 A1 PE20001047 A1 PE 20001047A1
Authority
PE
Peru
Prior art keywords
alkyl
formula
inhibitor
combination
group
Prior art date
Application number
PE1999000944A
Other languages
English (en)
Inventor
Jeffrey A Robl
Rex A Parker
Scott A Biller
Haris Jamil
Bruce L Jacobson
Krishna Kodukula
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22280975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20001047(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20001047A1 publication Critical patent/PE20001047A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)

Abstract

SE REFIERE A UN INHIBIDOR DE aP2 QUE CONTIENE UN HIDROGENO QUE ENLAZA UN GRUPO DONANTE O RECEPTOR FORMADOR DE PUENTES DE HIDROGENO DE NATURALEZA ACIDA Y UN SUSTITUYENTE DE NATURALEZA HIDROFOBICA SE CARACTERIZA PORQUE LA DISTANCIA ENTRE AMBOS ES DE 7 A° A 15 A°; TAL COMO a)UN BENZOILBENCENO O DERIVADO DEL ACIDO BIFENILALCANOICO DE FORMULA A(CH2)nO-B; A ES UN GRUPO a, b; X ES N, CR3; Z ES -R3C=CR3-, -R3C=N-, ENTRE OTROS; R1 ES H, ALQUILO, FENILO; R2 Y R3 SON H, ALQUILO; R1 Y R2 FORMAN UN BENCENO; CUANDO X ES N; Z ES -R3C=CR3-; n ES 1-2; B ES UN GRUPO c, d; Y ES OR5, NOHR8; R4 Y R5 SON H, ALQUILO; R6 ES H, HALOGENO, NITRO; R7 ES R4CHCOOR5, R4CHNOHCONH2, R4CHNOHCOR8, ENTRE OTROS; R8 ES ALQUILO; m ES 0-3; b)DERIVADO DE OXAZOL DE FORMULA II, DONDE R Y R` SON H, ALQUILO C1-C2; R1 Y R2 SON H, HALOGENO, ALQUILOXI, n ES 3-6. UN COMPUESTO PREFERIDO DE FORMULA A. TAMBIEN SE REFIERE A UNA COMBINACION QUE COMPRENDE ADEMAS UN AGENTE ANTIATEROESCLEROTICO TAL COMO PRAVASTATIN, LOVASTATIN, SIMVASTATIN, ATORVASTATIN, CERIVASTATIN, FLUVASTATIN. EL INHIBIDOR SE UNE A LA PROTEINA aP2(PROTEINA EN ADIPOSITO UNIDA A ACIDOS GRASOS) E INHIBE LA FUNCION DE UNIR ACIDOS GRASOS LIBRES Y PUEDE SER UTIL PARA TRATAR LA ATEROESCLEROSIS
PE1999000944A 1998-09-17 1999-09-17 METODO PARA TRATAR ATEROESCLEROSIS EMPLEANDO UN INHIBIDOR DE aP2 Y COMBINACION PE20001047A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10067798P 1998-09-17 1998-09-17

Publications (1)

Publication Number Publication Date
PE20001047A1 true PE20001047A1 (es) 2000-12-24

Family

ID=22280975

Family Applications (2)

Application Number Title Priority Date Filing Date
PE1999000944A PE20001047A1 (es) 1998-09-17 1999-09-17 METODO PARA TRATAR ATEROESCLEROSIS EMPLEANDO UN INHIBIDOR DE aP2 Y COMBINACION
PE1999000943A PE20001056A1 (es) 1998-09-17 1999-09-17 METODO PARA TRATAR DIABETES EMPLEANDO UN INHIBIDOR aP2 Y COMBINACION

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE1999000943A PE20001056A1 (es) 1998-09-17 1999-09-17 METODO PARA TRATAR DIABETES EMPLEANDO UN INHIBIDOR aP2 Y COMBINACION

Country Status (30)

Country Link
US (1) US20020035064A1 (es)
EP (2) EP1121129B1 (es)
JP (2) JP2002524518A (es)
KR (2) KR20010075150A (es)
CN (2) CN1319012A (es)
AT (1) ATE406898T1 (es)
AU (2) AU754488B2 (es)
BG (2) BG105431A (es)
BR (2) BR9913831A (es)
CA (2) CA2344300A1 (es)
CO (2) CO5130026A1 (es)
CZ (2) CZ2001964A3 (es)
DE (1) DE69939481D1 (es)
EE (2) EE04356B1 (es)
ES (1) ES2311306T3 (es)
GE (2) GEP20033044B (es)
HU (2) HUP0104108A2 (es)
ID (2) ID28450A (es)
IL (2) IL141785A0 (es)
LT (2) LT4870B (es)
LV (2) LV12687B (es)
NO (2) NO20011351L (es)
NZ (2) NZ510207A (es)
PE (2) PE20001047A1 (es)
PL (2) PL346661A1 (es)
SK (1) SK3202001A3 (es)
TR (2) TR200100773T2 (es)
UY (2) UY25714A1 (es)
WO (2) WO2000015229A1 (es)
ZA (2) ZA200207433B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1047423B1 (en) * 1997-11-19 2006-05-10 Takeda Pharmaceutical Company Limited Novel apoptosis inhibitors
CA2361335A1 (en) * 1999-02-12 2000-08-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
AU2005201289B2 (en) * 1999-02-12 2008-04-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP2004501066A (ja) 2000-01-28 2004-01-15 ブリストル−マイヤーズ　スクイブ　カンパニー 脂肪酸結合タンパク質のテトラヒドロピリミドンインヒビターおよび方法
HUP0500543A2 (hu) * 2000-11-20 2005-09-28 Bristol-Myers Squibb Company Piridonszármazékok mint aP2 inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
US20040143015A1 (en) * 2001-03-12 2004-07-22 Villhauer Edwin Bernard Combination of organic compounds
EP1414461A4 (en) 2001-07-13 2005-10-26 Bristol Myers Squibb Co PYRAZINONE INHIBITORS OF FATTY ACID BINDING PROTEIN AND METHOD
AU2002322585A1 (en) * 2001-07-20 2003-03-03 Adipogenix, Inc. Fat accumulation-modulating compounds
EP1443919A4 (en) 2001-11-16 2006-03-22 Bristol Myers Squibb Co DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
ATE490244T1 (de) 2003-01-27 2010-12-15 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
WO2004084890A1 (en) * 2003-03-26 2004-10-07 Crc For Asthma Limited Therapeutic and prophylactic compositions and uses therefor
WO2004096977A2 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Crystal structure of homo sapiens adipocyte lipid binding protein and uses thereof
JP5697296B2 (ja) 2004-03-05 2015-04-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
DE602005006806D1 (de) 2004-06-04 2008-06-26 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
MX2007009888A (es) 2005-02-17 2007-10-16 Synta Pharmaceuticals Corp Compuestos para el tratamiento de trastornos proliferativos.
US7709658B2 (en) 2005-07-26 2010-05-04 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
EP1951224A2 (en) * 2005-10-18 2008-08-06 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
WO2007143164A1 (en) * 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
WO2010056631A1 (en) * 2008-11-12 2010-05-20 Schering Corporation Inhibitors of fatty acid binding protein (fabp)
CN107149679B (zh) * 2009-03-05 2021-03-02 哈佛学院董事会 分泌的aP2及其抑制方法
JP6514282B2 (ja) * 2014-03-24 2019-05-15 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
JP6223376B2 (ja) * 2014-03-24 2017-11-01 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
WO2016176656A2 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
CA3026521A1 (en) * 2016-06-27 2018-01-04 President And Fellows Of Harvard College Compounds useful to treat metabolic disorders
CA3066733A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2129012A1 (de) 1971-06-11 1973-01-04 Merck Patent Gmbh Azol-derivate
FR2156486A1 (en) 1971-10-22 1973-06-01 Roussel Uclaf Oxazolyl oxy or thio acetic acids - analgesics antipyretics and anti-inflammatories
JPS5612114B2 (es) 1974-06-07 1981-03-18
GB1507032A (en) 1974-08-06 1978-04-12 Serono Lab 2-thiol-4,5-diphenyloxazole s-derivatives
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
NZ224733A (en) 1987-05-22 1990-12-21 Squibb & Sons Inc Organophosphorus hmg-coa reductase inhibitors; intermediates and compositions thereof
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
US5218124A (en) * 1989-10-27 1993-06-08 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
PT95690A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados substituidos de acidos benzoilbenzo-, bifenil- e 2-oxazol-alcanoicos, uteis como inibidores de pla2 e da lipoxigenase
US5262540A (en) * 1989-12-20 1993-11-16 Bristol-Myers Squibb Company [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
FR2663331B1 (fr) 1990-06-14 1994-05-06 Bellon Laboratoires Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB9019841D0 (en) * 1990-09-11 1990-10-24 Smith Kline French Lab Compounds
US5254576A (en) * 1992-04-03 1993-10-19 Bristol-Myers Squibb Company Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE4340781C3 (de) 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
PT736018E (pt) * 1993-12-20 2000-10-31 Fujisawa Pharmaceutical Co Derivados de 4,5-diariloxazol
US5599770A (en) 1994-07-15 1997-02-04 Kureha Kagaku Kogyo Kabushiki Kaisha Herbicidal composition containing 2-benzyloxypyrimidine derivatives, processes for producing the derivatives and 2-benzyloxypyrimidine derivatives
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
UA56992C2 (uk) 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
GB9600231D0 (en) 1996-01-05 1996-03-06 Foster Wheeler Petrol Dev Ltd Spacing bouy for flexible risers
AUPO134596A0 (en) 1996-08-01 1996-08-22 Jal Pastoral Co. Pty Ltd Demountable article carrier for motor vehicles
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

Also Published As

Publication number Publication date
TR200100773T2 (tr) 2001-07-23
EE200100154A (et) 2002-12-16
ID27833A (id) 2001-04-26
EP1121129A1 (en) 2001-08-08
LV12687A (en) 2001-07-20
EP1121129A4 (en) 2002-10-16
EP1113801A4 (en) 2002-10-02
AU755563B2 (en) 2002-12-12
CA2344309A1 (en) 2000-03-23
AU6387799A (en) 2000-04-03
ID28450A (id) 2001-05-24
ES2311306T3 (es) 2009-02-01
CO5130025A1 (es) 2002-02-27
IL141785A0 (en) 2002-03-10
US20020035064A1 (en) 2002-03-21
CN1319012A (zh) 2001-10-24
UY25713A1 (es) 2001-08-27
BG105432A (en) 2001-12-29
UY25714A1 (es) 2001-08-27
GEP20033045B (en) 2003-08-25
NO20011351L (no) 2001-05-11
LT2001022A (en) 2001-08-27
SK3202001A3 (en) 2002-04-04
BG105431A (en) 2001-12-29
NO20011352L (no) 2001-05-11
CZ2001964A3 (cs) 2002-01-16
LT2001023A (en) 2001-08-27
GEP20033044B (en) 2003-08-25
PL346660A1 (en) 2002-02-25
ATE406898T1 (de) 2008-09-15
JP2002524517A (ja) 2002-08-06
KR20010079842A (ko) 2001-08-22
LT4871B (lt) 2001-12-27
LV12686B (lv) 2001-10-20
CZ2001965A3 (cs) 2002-02-13
NO20011351D0 (no) 2001-03-16
EP1121129B1 (en) 2008-09-03
NZ510207A (en) 2003-08-29
EP1113801A1 (en) 2001-07-11
HUP0104240A2 (hu) 2002-03-28
EE200100155A (et) 2002-08-15
EE04356B1 (et) 2004-10-15
IL141786A0 (en) 2002-03-10
NO20011352D0 (no) 2001-03-16
TR200100774T2 (tr) 2001-12-21
NZ510209A (en) 2003-07-25
CN1317970A (zh) 2001-10-17
PE20001056A1 (es) 2000-12-24
BR9913831A (pt) 2001-05-29
ZA200207433B (en) 2003-10-27
CA2344300A1 (en) 2000-03-23
AU754488B2 (en) 2002-11-14
JP2002524518A (ja) 2002-08-06
KR20010075150A (ko) 2001-08-09
PL346661A1 (en) 2002-02-25
CO5130026A1 (es) 2002-02-27
HUP0104108A2 (hu) 2002-03-28
LV12687B (lv) 2001-10-20
LT4870B (lt) 2001-12-27
LV12686A (en) 2001-07-20
BR9913833A (pt) 2001-05-29
ZA200207430B (en) 2003-09-16
WO2000015230A1 (en) 2000-03-23
WO2000015229A1 (en) 2000-03-23
DE69939481D1 (de) 2008-10-16
AU6143799A (en) 2000-04-03

Similar Documents

Publication Publication Date Title
PE20001047A1 (es) METODO PARA TRATAR ATEROESCLEROSIS EMPLEANDO UN INHIBIDOR DE aP2 Y COMBINACION
PE20011294A1 (es) Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol
PE20081135A1 (es) Derivados que contienen sulfamoilo y sus usos
PE20011067A1 (es) Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicas
AR005706A1 (es) Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico
CO4920241A1 (es) Compuestos inhibidores de metaloproteasas heterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
AR008861A1 (es) COMPUESTOS DE LACTAMA E IMIDA HETEROCICLICOS DE ARALQUILO Y ARALQUILEDENO, COMPUESTOS INTERMEDIARIOS PARA SU SíNTESIS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN.
CO4900033A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas que los contienen .
EE200200045A (et) Asendatud oksoasaheterotsüklüülühendid, farmatseutiline kompositsioon ja vaheühendid
PE20001054A1 (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-amino sustituidas
SV1998000008A (es) Inhibisores de sulfamida-metaloproteasa. ref. ran 4070\114
CO4920240A1 (es) Compuestos inhibidores de metaloproteasa diheterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
DE60010675D1 (de) Caspase inhibitoren und deren verwendung
EA199800752A1 (ru) Пентафторбензолсульфонамиды и их аналоги
CO4900035A1 (es) Compuestos inhibidores de metaloproteasas 1,3-diheterocicli- cos, composiciones farmaceuticas que los contienen y metodos para utilizacion
EA199900303A2 (ru) Замещенные трициклические соединения
PE64398A1 (es) Derivados de azetidinona
CO4900045A1 (es) Compuestos inhibidores de metaloproteasas espirociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
ATE293691T1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
PE79599A1 (es) Derivados de 5&#39;-desoxicitidina
AR022824A1 (es) Inhibidores de metaloproteasa dihetero-sustituida
ES2065881T3 (es) Nuevos inhibidores de dopamina beta-hidroxilasa.
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
AR016824A1 (es) Composiciones solidas o semisolidas de uso oral, que contienen calcio y un acidulante; procedimiento para prerarar dichas composiciones; uso de compuestosde calcio como inhbidores de la erosion dental

Legal Events

Date Code Title Description
FC Refusal